PGLYRP1

Across TCGA pan-cancer cohorts, PGLYRP1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PGLYRP1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PGLYRP1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PGLYRP1 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

LUAD, HNSC, and COAD are the cancer types where PGLYRP1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PGLYRP1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−1.165	<.001	6	view →
HNSC	All	All	+0.428	<.001	6	view →
COAD	All	II,III,IV	+0.407	<.001	6	view →
PDAC	Female	II,III,IV	+1.525	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PGLYRP1–LUAD

Open the LUAD breakdown →